GFAP and neuroleptic malignant syndrome: Objectives: To measure plasma concentration of biomarkers of neurological damage (BDNF, GFAP, and S100B) in foals with NMS, foals presented for other diseases (sick‐foals), and healthy foals, and determine their association with outcome.